Abstract:Background: CD103+ Tissue-resident CD8+ T cells are previously reported as memory CD8+ T cells and thus could promote adaptive immune response. While immunotherapy shows a great potential in muscle-invasive bladder cancer (MIBC) treatment, it is urgent to discover which subgroup MIBC patients could benefit most from immunotherapy. We here tried to explore the prognostic and predictive value of CD103+ tissue-resident CD8+ T cells, and provide possible molecular explanations. Methods: We selected 259 MIBC patients who underwent radical cystectomy between 2002 and 2014. CD103+ tissue-resident CD8+ T Cells were evaluated via immunofluorescence of CD103 and CD8 performed in our constructed tissue microarrays. Prognostic value of CD103+ CD8+ T cells in MIBC was assessed, and was further validated in TCGA-BLCA cohort using tissue-resident CD8+ T cell core signatures. 10 fresh MIBC specimens were analyzed by flow cytometry to explore the anti-tumoral immune response and immune check-point expression of tissue-resident CD8+ T cell. Results: Patients with higher CD103+ tissue-resident CD8+ T cells infiltration had a significant better overall survival in both our study population and TCGA-BLCA cohort (HR = 0.504, 95%CI: 0.312-0.816; P = 0.005 and HR = 0.637, 95%CI: 0.444-0.913; P = 0.014). Further Cox regression indicated that CD103+ tissue-resident CD8+ T cells was an independent prognosticator in MIBC patients. Flow cytometry results revealed that CD103+ CD8+ T cells tended to express more IFN-γ and granzyme B than CD103- CD8+ T cells (P < 0.001 and P = 0.007, respectively) (n = 10). However, expression of perforin did not show significant differences between CD103+ CD8+ T cells and CD103- CD8+ T cells. We then analyzed PD-L1 and TIM3 expression in CD103+ tissue-resident CD8+ T cells. Surprisingly, there was no significant differences of PD-L1 expression between CD103+ CD8+ T cells and CD103- CD8+ T cells. Nonetheless, CD103+ CD8+ T cells had more TIM3+ phenotypes than CD103- CD8+ T cells (P = 0.034). Conclusions: High CD103+ tissue-resident CD8+ T cells could predict better prognosis in MIBC patients. Patients with high infiltration of CD103+ tissue-resident CD8+ T cells might benefit most from anti-TIM3 immunotherapy. Legal entity responsible for the study: Dai, Bo. Funding: National Natural Science Foundation of China; Shanghai Municipal Natural Science Foundation; Shanghai Municipal Commission of Health and Family Planning Program; Guide Project of Science and Technology Commission of Shanghai Municipality; Shanghai Cancer Research Charity Center. Disclosure: All authors have declared no conflicts of interest.

Integrative Score Based on CDK6, PD-L1 and TMB Predicts Response to Platinum-Based Chemotherapy and PD-1/PD-L1 Blockade in Muscle-Invasive Bladder Cancer

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

CXCR6 Expression Predicts Prognosis and Immunotherapeutic Benefit in Muscle-Invasive Bladder Cancer

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer

CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis

LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients

Integrating Angiogenesis Signature and Tumor Mutation Burden for Improved Patient Stratification in Immune Checkpoint Blockade Therapy for Muscle-Invasive Bladder Cancer

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer

Identification and Validation of an Excellent Prognosis Subtype of Muscle-Invasive Bladder Cancer Patients with Intratumoral CXCR5+ CD8+ T Cell Abundance.

B7-H4 Correlates with Clinical Outcome and Immunotherapeutic Benefit in Muscle-Invasive Bladder Cancer

Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling

CD19(+) Tumor-Infiltrating B-cells Prime CD4(+) T-cell Immunity and Predict Platinum-Based Chemotherapy Efficacy in Muscle-Invasive Bladder Cancer

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks

Intratumoral TIGIT + CD8 + T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

Machine Learning Prediction Models Based on Hub Genes Related to Immune Phenotypes in Muscle-Invasive Bladder Cancer Treated With Immune Checkpoint Blockade

A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer

CD103+ Tissue-Resident CD8+ T Cells Correlate with Protective Anti-Tumoral Immune Responses in Muscle-Invasive Bladder Cancer Patients.